Nature of the Event
The document is a Postal Ballot Notice issued to the members of AstraZeneca Pharma India Limited (the Company) to seek their approval, via remote e-voting, for a special resolution.
Key Resolution
The special resolution is for the appointment of Mr. Krishnamurthy Narayanan Iyer (DIN: 01726564) as an Independent Director of the Company.
Details of the Proposed Appointment
- Mr. Iyer was initially appointed as an Additional Director in the capacity of an Independent Director by the Board of Directors with effect from November 5, 2026, subject to shareholder approval.
- The resolution seeks to appoint him as an Independent Director, not liable to retire by rotation, for a term of 5 consecutive years from November 5, 2026, to November 4, 2031.
- The Company has received a notice in writing under Section 160 of the Companies Act, 2013, from a member proposing his candidature.
- Mr. Iyer has provided consent and a declaration confirming he meets the independence criteria under Section 149(6) of the Companies Act, 2013, and Regulation 16(1)(b) of the SEBI LODR Regulations.
- His proposed remuneration will be sitting fees and other remuneration as permitted under the Act, as recommended by the Nomination and Remuneration Committee. No specific amount is quantified.
- He holds no shares in the Company.
- He currently holds directorships in two other listed entities: Procter & Gamble Hygiene and Healthcare Limited and Gillette India Limited.
Profile of Mr. Krishnamurthy Narayanan Iyer
- Age: 69 years
- Qualifications: Bachelor of Commerce (Honours), Chartered Accountant (ICAI), Company Secretary (ICSI)
- Brief Profile: Has over four decades of leadership experience across retail, consumer products, banking, and financial services in India and internationally. Former Managing Director, President & CEO of Walmart India (2014-2020). He brings expertise in strategy, financial oversight, risk management, governance, consumer markets, and digital transformation.
Voting Details and Timeline
- Cut-off Date: Friday, November 13, 2026. Members registered as of this date are eligible to vote.
- E-voting Period: Commences at 9:00 AM IST on Wednesday, November 18, 2026, and ends at 5:00 PM IST on Thursday, December 17, 2026.
- Service Provider: The Company has engaged National Securities Depository Limited (NSDL) to facilitate the e-voting process.
- Scrutinizer: Mr. Vijayakrishna K.T, Practising Company Secretary (CP No. 980, FCS: 1788), has been appointed to scrutinize the e-voting process.
- Result Declaration: The Scrutinizer will submit his report to the Chairperson by Monday, December 21, 2026. The results will subsequently be placed on the Company's website (www.astrazeneca.com/india), NSDL's website (www.evoting.nsdl.com), and communicated to the BSE and the NSE.
- The resolution will be deemed passed on the last date of the voting period (December 17, 2026) if approved by the requisite majority.
Availability of Documents
The Notice and the draft letter of appointment for Mr. Iyer are available for inspection electronically. Members can request access via email to comp.secy@astrazeneca.com. The documents are also available on the Company's website and the websites of the stock exchanges (BSE and NSE).
Impact
As a governance-related appointment, the financial impact is not quantified in the disclosure. The appointment is intended to bring experienced independent oversight to the Company's Board.